These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27662849)

  • 1. Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.
    Haining RL; Jones TM; Hernandez A
    Neurochem Res; 2016 Dec; 41(12):3356-3363. PubMed ID: 27662849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Competition-Binding Assay to Determine Binding Affinity of Molecules to Neuromelanin via Fluorescence Spectroscopy.
    Fink J; Pathak H; Smith J; Achat-Mendes C; Haining RL
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31072013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
    Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.
    Double KL; Zecca L; Costi P; Mauer M; Griesinger C; Ito S; Ben-Shachar D; Bringmann G; Fariello RG; Riederer P; Gerlach M
    J Neurochem; 2000 Dec; 75(6):2583-9. PubMed ID: 11080212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems.
    Zareba M; Bober A; Korytowski W; Zecca L; Sarna T
    Biochim Biophys Acta; 1995 Jun; 1271(2-3):343-8. PubMed ID: 7605801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
    Ben-Shachar D; Youdim MB
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):139-50. PubMed ID: 8416600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromelanins in brain aging and Parkinson's disease: synthesis, structure, neuroinflammatory, and neurodegenerative role.
    Zucca FA; Capucciati A; Bellei C; Sarna M; Sarna T; Monzani E; Casella L; Zecca L
    IUBMB Life; 2023 Jan; 75(1):55-65. PubMed ID: 35689524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.
    Zecca L; Zucca FA; Wilms H; Sulzer D
    Trends Neurosci; 2003 Nov; 26(11):578-80. PubMed ID: 14585596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Sepia melanin as a PD model to describe the binding characteristics of neuromelanin - A critical review.
    Schroeder RL; Double KL; Gerber JP
    J Chem Neuroanat; 2015; 64-65():20-32. PubMed ID: 25681296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson's Disease.
    Ferrari E; Capucciati A; Prada I; Zucca FA; D'Arrigo G; Pontiroli D; Bridelli MG; Sturini M; Bubacco L; Monzani E; Verderio C; Zecca L; Casella L
    ACS Chem Neurosci; 2017 Mar; 8(3):501-512. PubMed ID: 28292181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis.
    Ferrari E; Engelen M; Monzani E; Sturini M; Girotto S; Bubacco L; Zecca L; Casella L
    J Biol Inorg Chem; 2013 Jan; 18(1):81-93. PubMed ID: 23111628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator.
    Haining RL; Achat-Mendes C
    Neural Regen Res; 2017 Mar; 12(3):372-375. PubMed ID: 28469642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.
    Fasano M; Bergamasco B; Lopiano L
    J Neural Transm (Vienna); 2006 Jun; 113(6):769-74. PubMed ID: 16755381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.
    Maruyama W; Shamoto-Nagai M; Akao Y; Riederer P; Naoi M
    J Neural Transm Suppl; 2006; (70):125-32. PubMed ID: 17017519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.